Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional
chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and
hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six
cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until
end of treatment, then followed for 52 weeks or until disease progression or discontinuation
due to toxicity or death.